

TOO EAGER FOR ITS AGE

TRADE INSTRUCTION

Immunogen (NASDAQ: IMGN) consistently overinvests in R&D. After 40 years, they should know how to make their investments payoff for investors. But they don't show any signs of bringing their investments in line with revenue. So, consider buying the January 21, \$5 Puts (IMGN220121P5) to turn their consistent overconfidence to your advantage.

Disclaimer: No financial advice is given or implied. Publisher is not a registered investment advisor or stockbroker. Information provided for educational purposes only.

Trading involves risk of loss and may not be suitable for everyone. You should carefully consider whether trading is suitable for you in light of your age, income, personal circumstances, trading knowledge, and financial resources. Only trade with money you can afford to lose. There is no guarantee that you will profit from your trading activity. Past performance is no guarantee future results.